The Managing Board of HELIX IMMUNO-ONCOLOGY S.A. with the registered office in Gliwice at the address: ul. Bojkowska 59C, 44-100 Gliwice, entered under identification number KRS: 0000692806 into the register of entrepreneurs in the National Court Register, maintained by the 10th Economic Department of the National Court Register at the District Court in Gliwice, with the initial capital of 1,321,950.00 PLN, fully paid, identified by tax-payer’s ID [NIP]: 5252547574, company ID [REGON]: 146535883 (hereinafter also referred to as the „Company”), while fulfilling the obligation resulting from Art. 16, clause 1, of the act of 30th August 2019, amending the Commercial Company Code and some other acts (Journal of Laws of 2019, item 1798, as further amended – hereinafter also referred to as the „Act”), hereby summons shareholders of HELIX IMMUNO-ONCOLOGY S.A. to submit Company share certificates (multiple share certificates) at the registered office of the Company by 31st January 2021.

Share certificates can be submitted at the office of the Company in Warsaw at the address: ul. Gen. Sylwestra Kaliskiego 2B, 00-908 Warsaw, from Monday till Friday, from 9:00 till 15:00. Share certificates are submitted at the Company’s office against a written receipt issued to the shareholder.

The Company would also like to inform shareholders that:

  1. The summons is related to obligatory dematerialization of shares imposed by the Act;
  2. The summons to submit share certificates is addressed to shareholders five times, in intervals that are not longer one month and not shorter than two weeks;
  3. The Company publishes an information note about the summons at the Company’s website, on the page dedicated to communication with shareholders, and does so for a period that is not shorter than three years since the date of publishing the first summons.
  4. The validity of share certificates issued by the Company shall expire by law as of 1st March 2021. As of that date, entries in the register of shareholders maintained by an entity appointed by a resolution of the General Meeting of Company Shareholders acquire legal force.
  5. A share certificate retains its force of evidence exclusively for the shareholder to prove to the Company that he has share-based property rights, and does so for the period of five years since the date, when the Act comes into force.
  6. The Company summoned shareholders individually to submit share certificates at the Company’s office and did so in a manner provided for convening a General Meeting of Company Shareholders.

The Managing Board of the Company:
Ireneusz Fąfara – President of the Managing Board
Paweł Wiśniewski – Vice-President of the Managing Board